Search Results

You are looking at 51 - 60 of 71 items for :

Clear All
Full access

Bradford R. Hirsch and Gary H. Lyman

; 19 : 753 – 759 . 38 Watts MJ Addison I Long SG . Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers . Br J Haematol 1997 ; 98 : 474 – 479 . 39 Pinto L Liu Z Doan Q

Full access

Abiy Agiro, Andrea DeVries, Jennifer Malin and Michael J. Fisch

; 23 : 4198 – 4214 . 31. Tan H Tomic K Daniel G . Evaluating the risk of hospitalization with G-CSF use in real-world oncology practice [abstract] . J Clin Oncol 2009 ; 27 ( Suppl ): Abstract 6626 . 32. Trillet-Lenoir V Green J

Full access

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre and Gary H. Lyman

. Available at: NCCN.org . Accessed June 8, 2015 . 7. Chao C Page J Yang S . History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis . Ann Oncol 2014 ; 25 : 1821

Full access

supportive care were also examined. Results: nab-P was associated with significantly longer TTD than eribulin in HR+/HER2− MBC ( Table 1 ). Granulocyte colony-stimulating factor (G-CSF) and antiemetics were used less with nab-P in both HR+/HER2− and TN MBC

Full access

Peter E. Clark, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, A. Karim Kader, Adam S. Kibel, Timothy M. Kuzel, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer and Courtney Smith

year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours . Eur J Cancer 2006 ; 42 : 50 – 54 . 36 Plimack ER Hoffman-Censits JH Viterbo R

Full access

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer and Lisa A. Gurski

Mulder P Schornagel JH . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours . Eur J Cancer 2006 ; 42 : 50 – 54 . 38. De Santis M Bellmunt J Mead G

Full access

David Y. Oh, Alan P. Venook and Lawrence Fong

dendritic cell vaccination. These approaches have used autologous dendritic cells, unmobilized or mobilized with agents such as Flt3 or granulocyte colony-stimulating factor (G-CSF), then loaded with peptides derived from CEA and administered to small

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

prophylactic use of recombinant granulocyte colony–stimulating factors (G-CSF) has confirmed their effectiveness in reducing the risk of febrile neutropenia. 214 Some concerns have been expressed that the combination of growth factors and topoisomerase II

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans and Cary P. Gross

), and 25% of all patients treated with chemotherapy would receive granulocyte colony-stimulating factor (G-CSF) pegfilgrastim (on average 2 cycles) for the secondary prevention of febrile neutropenia. 18 For patients who did not receive ODX testing, we

Full access

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward and Eric P. Winer

prophylaxis with granulocyte-colony stimulating factors (G-CSF) versus placebo or untreated controls in patients undergoing chemotherapy indicated that G-CSF therapy was associated with decreased incidences of febrile neutropenia and early death, and a higher